IKZF1 and acute lymphoblastic leukemia: Those with high-risk disease, including patients with IKZF1-deleted B-ALL, received intensified therapy, including higher doses of methotrexate, three blocks of delayed intensification, and two additional chemotherapy cycles containing fludarabine, cytarabine, and daunorubicin [84,85].